MXPA06009711A - Uso de carboxipeptidasa g para combatir la toxicidad de antifolato. - Google Patents

Uso de carboxipeptidasa g para combatir la toxicidad de antifolato.

Info

Publication number
MXPA06009711A
MXPA06009711A MXPA06009711A MXPA06009711A MXPA06009711A MX PA06009711 A MXPA06009711 A MX PA06009711A MX PA06009711 A MXPA06009711 A MX PA06009711A MX PA06009711 A MXPA06009711 A MX PA06009711A MX PA06009711 A MXPA06009711 A MX PA06009711A
Authority
MX
Mexico
Prior art keywords
carboxypeptidase
combating
compound
antifolate
formula
Prior art date
Application number
MXPA06009711A
Other languages
English (en)
Inventor
Roger Melton
Anthony Atkinson
Original Assignee
Protherics Medicines Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Protherics Medicines Dev Ltd filed Critical Protherics Medicines Dev Ltd
Publication of MXPA06009711A publication Critical patent/MXPA06009711A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Un metodo para combatir la toxicidad causada por un compuesto de antifolato de formula (I), en una persona a quien se ha administrado el compuesto; el metodo comprende administrar una enzima que tiene actividad de carboxipeptidasa G a la persona; un metodo para escindir un compuesto que comprende un fragmento estructural de formula (VIII), el metodo comprende poner en contacto el compuesto que comprende el fragmento estructural de formula (VIII) con una enzima que tiene actividad de carboxipeptidasa G.
MXPA06009711A 2004-02-28 2005-02-28 Uso de carboxipeptidasa g para combatir la toxicidad de antifolato. MXPA06009711A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0404487.1A GB0404487D0 (en) 2004-02-28 2004-02-28 Use of enzyme
PCT/GB2005/000751 WO2005084695A2 (en) 2004-02-28 2005-02-28 Use of carboxypeptidase g for combating antifolate toxicity

Publications (1)

Publication Number Publication Date
MXPA06009711A true MXPA06009711A (es) 2007-05-16

Family

ID=32051060

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA06009711A MXPA06009711A (es) 2004-02-28 2005-02-28 Uso de carboxipeptidasa g para combatir la toxicidad de antifolato.

Country Status (13)

Country Link
US (1) US20070243182A1 (es)
EP (1) EP1727548A2 (es)
JP (1) JP2007524711A (es)
KR (1) KR20070036023A (es)
CN (1) CN1950088A (es)
AU (1) AU2005218987A1 (es)
BR (1) BRPI0508053A (es)
CA (1) CA2557610A1 (es)
GB (1) GB0404487D0 (es)
IL (1) IL177647A0 (es)
MX (1) MXPA06009711A (es)
WO (1) WO2005084695A2 (es)
ZA (1) ZA200607171B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1917027A2 (en) * 2005-08-24 2008-05-07 Protherics Medicines Development Limited Cleavage of antifolate compounds
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
US20100260825A1 (en) * 2009-04-13 2010-10-14 Nair Madhavan G Antifolates for the treatment of cardiovascular, inflammatory, neoplastic, autoimmune and related diseases in sublingual dosage units, film strips, or skin patches
EP2266984A1 (en) * 2009-06-26 2010-12-29 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Pyrido[2,3-d]pyrimidines as Wnt antagonists for treatment of cancer and arthritis
US8404859B2 (en) * 2011-03-16 2013-03-26 Hoffmann-La Roche Inc. Thiazole and thiophene compounds
EP4313314A1 (en) * 2021-03-30 2024-02-07 Genecentric Therapeutics, Inc. Methods for assessing proliferation and anti-folate therapeutic response

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0011060D0 (en) * 2000-05-08 2000-06-28 Cancer Res Campaign Tech Improvements relating to gene directed enzyme prodrug therapy

Also Published As

Publication number Publication date
WO2005084695A3 (en) 2005-12-08
GB0404487D0 (en) 2004-03-31
US20070243182A1 (en) 2007-10-18
CA2557610A1 (en) 2005-09-15
WO2005084695A2 (en) 2005-09-15
EP1727548A2 (en) 2006-12-06
KR20070036023A (ko) 2007-04-02
ZA200607171B (en) 2007-11-28
JP2007524711A (ja) 2007-08-30
AU2005218987A1 (en) 2005-09-15
BRPI0508053A (pt) 2007-07-17
CN1950088A (zh) 2007-04-18
IL177647A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
WO2007023243A3 (en) Cleavage of antifolate compounds
ZA200810113B (en) Method for the treatment and prevention of ocular disorders
TNSN08140A1 (es)
TW200740429A (en) Methods and dosage forms for reducing side effects of carbamate compounds
WO2011127070A3 (en) IRE-1α INHIBITORS
WO2008124085A3 (en) Methods of using combinations of mek and jak-2 inhibitors
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
TNSN08178A1 (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2009004475A (es) Composiciones que comprenden agentes acido labiles que inhiben la bomba de protones, por lo menos otro agente farmaceuticamente activo y metodos de uso de las misma.
SG160364A1 (en) Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer
GEP20104941B (en) Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods
WO2007123995A3 (en) Camptothecin-analog with a novel, “flipped” lactone-stable, e-ring and methods for making and using same
WO2008148074A3 (en) Inhibitors of mtor and methods of treatment using same
HU0302788D0 (en) New compounds
MXPA06009711A (es) Uso de carboxipeptidasa g para combatir la toxicidad de antifolato.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych
WO2006088814A3 (en) Dosage form and method for sustained release of a substituted pyrazine compound
DE60125417D1 (de) Verminderung der nebenwirkungen der chemotherapie in krebspatienten
TW200621785A (en) Analgesic
MX2007002833A (es) Derivados de alquiliden-tetrahidronaftaleno, procedimiento para su preparacion y su uso como antiinflamatorios.
MX2010003594A (es) Formas cristalinas de sal sodica de dmxaa.
TWI349545B (en) Pharmaceutical composition
TW200503666A (en) Treatment of type 1 diabetes with pde5 inhibitors
WO2008041116A3 (en) Formulations of active principles incorporated in slns suitable for transdermal administration